Regeneration Technologies Inc.'s VEGF Trap Demonstrates Positive Preliminary Results In Patients With Age-Related Macular Degeneration
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Feb. 2, 2006--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today positive preliminary results from an ongoing phase 1 dose-escalation study of the Vascular Endothelial Growth Factor Trap eye formulation ("VEGF Trap - Eye") in 18 patients with the neovascular form of age-related macular degeneration (wet AMD). Patients have shown rapid, substantial, and prolonged (up to at least 4 weeks) reductions in retinal thickness as measured by optical coherence tomography (OCT). Patients in this trial have received a single dose of the VEGF Trap at levels up to 2 milligrams (mg) intravitreally (direct injection into the eye). A maximum tolerated dose has not been reached, and there has been no evidence of ocular inflammation. Additional patients are now being tested at the 4 mg dose level. Patients are being followed for three months after dosing.